Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume -, Issue -, Pages 201700363
Publisher
Proceedings of the National Academy of Sciences
Online
2017-07-15
DOI
10.1073/pnas.1700363114
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3
- (2016) Zhaoxia Zou et al. JOURNAL OF NEUROSURGERY
- Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways
- (2016) Laurent A. Bentolila et al. Scientific Reports
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- The Biology of Brain Metastasis
- (2015) Isaiah J. Fidler CANCER JOURNAL
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy
- (2015) Kevin J Harrington et al. Expert Review of Anticancer Therapy
- Genetically Modified Murine Adipose-Derived Mesenchymal Stem Cells Producing Interleukin-2 Favor B16F10 Melanoma Cell Proliferation
- (2015) Vahid Bahrambeigi et al. IMMUNOLOGICAL INVESTIGATIONS
- Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment
- (2015) Sean E. Lawler et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.
- (2015) Paul D. Brown et al. JOURNAL OF CLINICAL ONCOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
- (2015) Valerio Leoni et al. Oncotarget
- Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy
- (2014) Matthias Duebgen et al. JNCI-Journal of the National Cancer Institute
- The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
- (2014) J. A. Lo et al. SCIENCE
- Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells
- (2013) Sandra A Jacobs et al. IMMUNOLOGY AND CELL BIOLOGY
- Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer
- (2013) Emily K Mader et al. Journal of Translational Medicine
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
- (2013) T. A. Cheema et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical applications of mesenchymal stem cells
- (2013) Nayoun Kim et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Melanoma brain metastasis: overview of current management and emerging targeted therapies
- (2012) Ekokobe Fonkem et al. Expert Review of Neurotherapeutics
- Melanoma: from mutations to medicine
- (2012) H. Tsao et al. GENES & DEVELOPMENT
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Multimechanistic Tumor Targeted Oncolytic Virus Overcomes Resistance in Brain Tumors
- (2012) Kaoru Tamura et al. MOLECULAR THERAPY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors
- (2012) Faruk Tas Journal of Oncology
- Mesenchymal stem cells engineered for cancer therapy
- (2011) Khalid Shah ADVANCED DRUG DELIVERY REVIEWS
- New strategies to deliver anticancer drugs to brain tumors
- (2009) Valentino Laquintana et al. Expert Opinion on Drug Delivery
- Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy
- (2009) Candice Willmon et al. MOLECULAR THERAPY
- Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
- (2009) L. S. Sasportas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice
- (2008) Y Kulu et al. CANCER GENE THERAPY
- Bimodal Viral Vectors and In Vivo Imaging Reveal the Fate of Human Neural Stem Cells in Experimental Glioma Model
- (2008) K. Shah et al. JOURNAL OF NEUROSCIENCE
- Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
- (2008) Roberto Cattaneo et al. NATURE REVIEWS MICROBIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started